José Luis Rodríguez

Oncólogo médico 🦀🧬

[José Luis Rodríguez @JoseLuisROli]

🐶🤩

[CancerNetwork® @CancerNetwrk]

The July issue of @CancerNetwrk's ONCOLOGY is live: new HRR/MMR data in advanced prostate cancer, a Face-Off on CAR T in DLBCL, and more. @drgoodyear @PBarataMD @BourlonMaite @niravshahmd @KUcancercenter @ASCO
Read: https://t.co/J4b6PkCZeQ

[NEJM @NEJM]

Presented at #ASCO26:

Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: https://t.co/xwLWBZYRzq

@ASCO

[Víctor Domínguez @victrdgz]

Such an incredible experience presenting last weekend at @LatinoSurgery! Thank you @DavidCabaMD for the kind words and the guidance. Proud of the work our team is doing @CenterRuhs @LLUSurgOnc 🇲🇽🔬🧬🩺 #LSS2026 #SurgicalOncology

[David Caba MD,MS,MPH,MBA,FACS @DavidCabaMD]

Congrats to our fellow @victrdgz for an outstanding presentation of our work @LatinoSurgery meeting in Chicago. @CenterRuhs @LLUSurgOnc @rajarnarayan @EmanuelEguia @UChicago

[Dirección de Investigación INCMNSZ @INCMNSZ_DirInv]

Saber no siempre es actuar: Un estudio en centros de referencia de México muestra que, aunque los portadores de genes de riesgo de cáncer tienen un conocimiento aceptable, esto no garantiza que opten por intervenciones.Participación del@incmnszmx, Alejandro Aranda Gtez y cols.

[Maite Bourlon @BourlonMaite]

@incmnszmx we were happy to receive @PBarataMD to discuss about #ProstateCancer 👨🏻‍⚕️👩🏻‍⚕️🌍🇲🇽

Multidisciplinary discussion w Urology, Genetics and pathology 📘🖇️🗂️💙

@JoseLuisROli @sof_mb @Elias31222749

[Matt Yurgelun, MD @MattYurgelun]

There’s still time to join us for our @DanaFarber #LynchSyndrome Scientific Symposium all day Wed April 16.

Available virtually or in-person for FREE!

Register at: https://t.co/dkOaWuwME7

[Regina Barragan-Carrillo @ReginaBarCar]

🧐 Did you miss any key studies in 2024?
Don't worry, the #OncoAlert Colloquium has EVERYTHING covered! 🏆
🎯 An excellent resource for Oncology residents.

Check it out here 👉 🔗 https://t.co/JAQ0uIFf0U

@SMEOMX @Betzabe100 @incanMX @OscarTahuahua @HeRagosan @JoseLuisROli @PaolaVS94

[Dirección de Investigación INCMNSZ @INCMNSZ_DirInv]

Estudio muestra el proceso de establecimiento y adaptación de un programa de oncogenética en México, participación del @incmnszmx , @yaninchavarri y Cols.

[Andres Meraz-Brenez @iandresmeraz]

Proud to be part of this important study on CDK4/6 inhibitor preferences in Latin America. Grateful for the opportunity to collaborate and contribute to improving breast cancer care. #SABCS24 @labca_ok @Dra_CVillarreal @Agatharm @alexarandag

[CGA-IGC @CGAIGC]

📢Happening this week in collaboration w/@geth_org‼️

🗓️Fri Dec 13
⏲️12.30pm ET / 9.30am PT

➡️The webinar features 4⃣leading experts, two from each society, who will share their insights & experiences on #HereditaryGICancer syndromes‼️

📍#CGAIGC members, check your 📥for the📨you received from us today‼️

➡️Not a member but want to watch this webinar & others on demand? Join here 👉https://t.co/pZ8hEycTUT

[Ed Esplin, MD, PhD @EdEsplin]

'Influence of Preoperative #LynchSyndrome Diagnosis (i.e. #GermlineTesting) on the Extent of Surgery in #Patients w/ #ColonCancer' @abbassmohd @MSKCancerCenter w/ @Invitae @Labcorp @CGAIGC #CGAIGC24

48% of #CRC #patients w/ #LS on #genetictesting pre-surgery had total colectomy

19% of #CRC #patients w/ #LS on #genetictesting post-surgery had total colectomy

#Universal presurgical #germlinetesting for all #patients w/ #CRC

#access #reducedisparities #precisionsurgery #precisionmedicine #precisiontherapy #clinicaltrials #precisionprevention

[Erman Akkus @Erman_Akkus]

💊Aspirin (ASA) and NSAID Chemoprevention Uptake in Patients With Lynch Syndrome
@JCOPO_ASCO

🚨Uptake is 34.8%
🚨55% were taking <100 mg ASA

➡️CAPP2 randomized double-blind placebo-controlled trial: 60% RR reduction for CRC with 600mg ASA

👉https://t.co/4Pd7Rjo4nU

@ASCO @JCOOP_ASCO @OncoAlert @Lynchsyndromirl #cancer #oncology #MedX

[CGA-IGC @CGAIGC]

Pancreatic cancer in women with BRCA1/2 - Bryson Katona

#CGAIGC24

Prospective data - the annual risk is low 0.03% !

Risk factors: BRCA2 (vs BRCA1), first degree relative with pancreatic cancer, heavy alcohol use, new onset diabetes

[CGA-IGC @CGAIGC]

Hepatobiliary cancers: germline genetic associations- great talk by ⁦@KirkWangensteen⁩ #CGAIGC24

[CGA-IGC @CGAIGC]

Gastrointestinal cancer risks and management in Li-Fraumeni syndrome, great talk by ⁦@KMaxwellLab⁩ #CGAIGC24

[Maite Bourlon @BourlonMaite]

Congrats to our fellows for this paper!
@EvelynBeas2 @HeRagosan @JoseLuisROli

🔵Overview of hereditary cancer syndromes associated w RCC
🟡Recommendations for genetic testing
🟢Tuberous sclerosis complex symptoms and mTOR inhibitors efficacy &amp; safety

https://t.co/bARRny7eoI

[Dirección de Investigación INCMNSZ @INCMNSZ_DirInv]

Estudio que ilustra la necesidad de realizar pruebas de panel multigénico para la evaluación del riesgo de cáncer genético en mexicanos con con cáncer de páncreas exocrino. Doi: 10.1016/j.pan.2024.09.018, participación del @incmnszmx José Luis Rodríguez Olivares y cols.

[Dirección de Investigación INCMNSZ @INCMNSZ_DirInv]

Hallazgos sobre la variante patogénica en los genes MMR de la enfermedad de Lynch y describe el fenotipo en pacientes mexicano-mestizos y sus familiares. DOI: 10.1016/j.heliyon.2024.e31855, participación del @incmnszmx , Pamela Rivero-García, @yaninchavarri #enfermedadLynch

[Heliyon @HeliyonJournal]

Lynch syndrome in Mexican-Mestizo families: Genotype, phenotypes, and challenges in cascade testing among relatives at risk https://t.co/oLkS8BhDMQ